Stolen From a Bacterial Immune System
CRISPR gene editing — the acronym stands for clustered regularly interspaced short palindromic repeats — is a genetic engineering technique by which the genomes of living organisms can be modified.
The elegant part is where it came from. It is based on a simplified version of the bacterial CRISPR-Cas9 antiviral defence system: an immune mechanism bacteria evolved to recognise and cut up invading viruses. Researchers did not design the tool so much as domesticate one.
It works by delivering the Cas9 nuclease into a cell, paired with a synthetic guide RNA that specifies the target. The cell's genome is then cut at the chosen location, allowing genes to be removed or added in vivo — within the living organism. Cas9 itself is derived from the bacterium *Streptococcus pyogenes*, and the guide strands, crRNA and tracrRNA, are what tell it where to cut.
Two Ways to Repair a Cut
Cutting DNA is only half the operation. What matters is how the cell repairs the break, and there are two routes with very different outcomes.
Knock-in mutations use homology-directed repair (HDR), the traditional approach to targeted editing. HDR uses similar DNA sequences to drive repair, incorporating exogenous DNA as a template — which is how you insert something specific.
Knock-out mutations happen when the double-stranded break is repaired instead by non-homologous end joining (NHEJ) or TMEJ. These pathways often produce random deletions or insertions at the repair site, disrupting or altering the gene's function. That sounds like a defect, and it is also useful: it lets researchers generate targeted random gene disruption deliberately, to find out what a gene does by breaking it.
Why This One Changed Everything
Genome editing in eukaryotic cells had been possible by various methods since the 1980s. The problem was that those methods were inefficient and impractical at any real scale.
Cas9 changed the economics. It made editing efficient and highly selective, providing a reliable way to create a break at a precise location. Researchers can now insert Cas9 and a template RNA easily, in order to silence genes or cause point mutations at specific sites — invaluable for quickly mapping which genes drive which biological processes.
The technique is considered exceptionally precise, cost-effective and efficient, with applications across new medicines, agricultural products, genetically modified organisms, and controlling pathogens and pests. Newly engineered Cas9 variants have been developed that significantly reduce off-target activity. Jennifer Doudna and Emmanuelle Charpentier won the 2020 Nobel Prize in Chemistry for the development of the technique — while a third group led by Virginijus Šikšnys, which shared the Kavli Prize for the same discovery, was not included.
From Breakthrough to Medicine
The CRISPR-Cas9-gRNA complex was the AAAS Breakthrough of the Year in 2015, and since then it has moved from laboratory to clinic with unusual speed.
In 2023 the first drug using CRISPR gene editing — exagamglogene autotemcel, sold as Casgevy — was approved in the United Kingdom to treat sickle-cell disease and beta thalassemia. Bahrain approved it on 2 December 2023, and the US FDA followed on 8 December 2023.
The ethical line is elsewhere, and it has already been crossed. CRISPR has been investigated on non-viable human embryos since 2015, and in 2019 the first humans were born from genome-edited embryos, in the controversial He Jiankui affair. Editing a patient's own cells is one thing; editing the germline changes every descendant, and has raised serious bioethical concerns — particularly the prospect of enabling human eugenics.
